Sanofi has entered into a collaboration and license agreement with Alloy Therapeutics to develop an antisense oligonucleotide ... field include Biogen’s ASO Spinraza (nusinersen) approved ...

The drug candidate acts by targeting transthyretin (TTR) protein. It is developed based on ligand conjugated antisense technology (LICA) platform. GlobalData, the leading provider of industry ...

Its major products include Spinraza for spinal muscular atrophy ... It develops products based on its proprietary antisense technology. The company partnered with other pharmaceutical companies to ...